| Name | Title | Contact Details |
|---|
Farmers Life Insurance Company ("Farmers Life") was founded in 1997 as a small credit life and disability insurance company and has flourished by providing secure insurance products that address a growing number of diverse consumer needs. In a fast-paced industry, we strive to deliver best-in-class service throughout the life of our policies ensuring that people can fund their retirements, secure their legacies and enjoy the peace of mind associated with a well-planned future.
Atosa is a major manufacturer of commercial kitchen equipment, with a breadth of offering including refrigeration, cooking equipment, warming/holding equipment, stainless steel fabrication equipment, and much more. Atosas world-class manufacturing facilities and highly skilled employees, combined with innovative manufacturing procedures ensure that our customers always receive top-quality products at economical prices.
XNRGY Climate Systems is a Montreal-based company that designs, develops, and manufactures HVAC systems with a strong emphasis on energy efficiency and sustainability. Founded in 2017, the company aims to lead North America in sustainable design and advanced manufacturing of custom air handling systems, particularly for data centers, healthcare facilities, clean rooms, and life sciences environments. The company offers custom-engineered air handling units tailored to meet specific project requirements, focusing on reducing power usage effectiveness and carbon footprints. XNRGY specializes in thermal management solutions, ensuring optimal cooling and heating for mission-critical facilities. Its product lineup includes custom air handlers, energy recovery systems, and specialized materials designed to meet demanding specifications. XNRGY serves a diverse clientele, including major cloud and hyperscale data center operators, healthcare facilities, and life sciences organizations, ensuring high standards of air quality and efficiency.
Fresh Kitchen is a healthy fast-casual restaurant chain founded in 2014 and based in Boca Raton, Florida. The restaurant specializes in 100% gluten-free, customizable meals that cater to various dietary preferences, including vegan, keto, and carnivore diets. Their menu features high-quality, scratch-made recipes using fresh ingredients, antibiotic-free and hormone-free meats, homemade sauces, and hand-cut vegetables cooked in 100% olive oil. Customers can create their own balanced bowls by selecting from a variety of bases, freshly roasted vegetables, grilled or roasted meats, and flavorful toppings. Fresh Kitchen also offers daily in-house pressed juices, teas, and juice frescas, with seasonal recipes to ensure freshness. The company emphasizes fast service without compromising quality, aiming to support active lifestyles. In addition to their food offerings, Fresh Kitchen is dedicated to community impact and sustainability. They engage in local givebacks, food donations, and composting, supporting causes that align with their values. With around 64 employees and reported revenue of $31.2 million, Fresh Kitchen is recognized for combining convenience, quality, and social responsibility in the healthy fast food sector.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.